Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Fig. 1

PRL-3 expression level confers prognostic value for AML patients. a Overall survival analysis of patients with PRL-3 high vs PRL-3 low. b Overall survival analysis of patients with PRL-3 Q4 vs PRL-3 Q1. Survival curves were constructed according to the Kaplan-Meier method. PRL-3 high ≥ median value; PRL-3 low < median value. Statistical significance was considered when p < 0.05. HR hazard ratio

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us